Medable teams with the AHA to develop Human Heart Digitome

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/BrianAJackson)
(Image: Getty/BrianAJackson)

Related tags RWD Real world data Medable cardiovascular disease

Medable joins the AHA’s ‘Innovators Network’ to develop the Human Heart Digitome, which is expected to be the largest real-world database dedicated to advancing cardiovascular disease research and patient care, says CEO.

Medable has joined the American Heart Association (AHA) Center for Health Technology and Innovation Innovators Network.

The center and Innovators Network “builds and harnesses health technologies and relationships in pursuit of innovative and scalable solutions across the health continuum and in alignment with AHA health goals,” ​explained Dr. Michelle Longmire, CEO and co-founder of Medable.

“The center aims to give the patient a more substantive and influential voice in the evolution of digital health technology, and to allow health tech companies more meaningful opportunities to engage providers and patients on a personal level,”​ she told us.

In pursuit of these goals, the center established the Health Tech Collaborative, a consortium of collaborations to formally link entrepreneurs, providers, researchers, and patients, explained Longmire.

As a network member, the team at Medable will work with the center to develop the Human Heart Digitome, which she said is expected to be “the largest real-world database specifically for the understanding and treatment of cardiovascular disease.”

The platform aims to improve patient care by providing patients with personalized health management plans and advance research by collating patient-reported outcomes (PROs), information from connected devices and electronic medical records (EMRs), as well as clinical outcomes assessment data.

“The focus is on the patient,” ​said Longmire, “as individual data in the registry will not only be used in research and clinical trials, but will also be analyzed with Medable's predictive analytics tools to help physicians identify at-risk patients and improve outcomes in the treatment of cardiovascular diseases.”

The Palo Alto, CA-headquartered company earlier this year​ was awarded two Fast-Track Small Business Innovation (SBIR​) grants from the National Cancer Institute (NCI) totaling up to $3.5m to further develop its end-to-end platform for digitally-enabled clinical trials, which can be used at an individual, study, or population level.

The funding is, in part, supporting the development and validation of the mobile application TogetherCare (Track Outcomes and Guidance, Technology for Health and Effective Resources). The application is built on a smart software system and can be used by caregivers to develop and implement home-based care for cancer survivors.

The second award is funding development of Medable’s cloud-based platform, DigiBioMarC (Digital BioMarkers for Clinical Impact), which provides an informatics tool for automated data aggregation, integration, and machine learning algorithms to support clinical trials and patient care.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more